Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
The disclosure provides a method of treating chronic cough in a subject having idiopathic pulmonary fibrosis (IPF) comprising administering to the subject a pharmaceutical composition comprising from about 2% by weight to about 6% by weight of cromolyn sodium and an ionic osmotic agent with a nebulizer.
1. A method of treating chronic cough in a subject having idiopathic pulmonary fibrosis, comprising:
(a) determining whether a subject has chronic cough due to idiopathic pulmonary fibrosis or chronic idiopathic cough;
(b) selecting for treatment only a subject having chronic cough due to idiopathic pulmonary fibrosis; and
(c) administering to the subject determined to have chronic cough due to idiopathic pulmonary fibrosis a therapeutically effective amount of a pharmaceutical composition comprising cromolyn sodium with an inhalation device.
2. The method of claim 1 , wherein the inhalation device is selected from a nebulizer, a dry powder inhaler, and a jet nebulizer.
3. The method of claim 2 , wherein the inhalation device is a jet nebulizer.
4. The method of claim 2 , wherein the inhalation device is a nebulizer.
5. The method of claim 1 , wherein the pharmaceutical composition comprises greater than 1% by weight of cromolyn sodium.
6. The method of claim 1 , wherein the pharmaceutical composition comprises about 4% by weight of cromolyn sodium.
7. The method of claim 1 , wherein the pharmaceutical composition comprises about 6% by weight of cromolyn sodium.
8. The method of claim 1 , wherein the pharmaceutical composition comprises from about 5 mg to about 80 mg of cromolyn sodium, inclusive of the endpoints.
9. The method of claim 8 , wherein the pharmaceutical composition comprises from about 36 mg to about 44 mg of cromolyn sodium, inclusive of the endpoints.
10. The method according to claim 1 , wherein the pharmaceutical composition is administered to the subject from once to five times per day.
11. The method according to claim 1 , wherein the pharmaceutical composition is administered to the subject three times per day.
12. The method according to claim 10 , wherein the pharmaceutical composition is administered to the subject for 14 days or more.
13. The method of claim 2 , wherein the inhalation device is a dry powder inhaler.
14. The method of claim 13 , wherein the pharmaceutical composition comprises about 2% by weight of cromolyn.
15. The method of claim 1 , wherein administration of the pharmaceutical composition to the subject with the inhalation device provides in the subject a bioavailability of cromolyn greater than about 5%.
16. The method of claim 1 , wherein administration of the pharmaceutical composition to the subject with the inhalation device provides in the subject a deposited lung dose of cromolyn greater than about 4 mg.